Showing posts with label US. Show all posts
Showing posts with label US. Show all posts

ReportsandReports - OTC Opportunities in Europe, the US and Japan: Key trends, leading players and future Rx-OTC switching



The developed OTC markets such as the US and UK are heavily reliant on Rx-to-OTC switching of “new generation” products as a means of generating growth. Switching also plays an important role for less-developed markets (e.g. France, Spain, Italy, Japan), though in this case they are playing “catch-up” with the more developed markets. The “Power of Switch” was brought into sharp focus in 2009 with the first ever use of the Centralized Procedure for switching products throughout the European Union. This comprehensive report provides background on market dynamics (including overall market size and therapeutic category size) for each of the core countries under analysis.

This report also examines products and categories that are likely to be switched in the future, regulatory changes that are likely to impact the OTC market, and provides growth forecasts to 2013. Included in the report are case studies for two of the most significant switches of recent years – i.e. Alli (orlistat) and Zocor (simvastatin).

Key features of this report
  • Comprehensive examination of recent trends and developments in the featured countries.
  • Market sizes and category sizes in 7 core markets.
  • Case studies of the switches of orlistat and statins.
  • Examination of regulatory changes that are likely to impact upon OTC markets in the future
Scope of this report
  • Provides a clear and concise understanding of the dynamics of the global OTC market.
  • Demonstrates how the dynamics of the OTC markets in the various countries differ widely, but also how they relate to each other.
  • Identifies and examines examples of successful switches, which can be used as a model for future switches.
  • Highlights switches that failed and examines possible causes for failure.
  • Allows marketers to plan ahead: Anticipating what switches are likely to take place in future; and take into account other regulatory changes that are likely to take place.
Key Market Issues
  • In 2008, the global pharmaceutical market grew by 4.8% to reach $773bn (MSP), while the global OTC market grew by 7.6% to reach $79.3bn (MSP). Although OTC growth in recent years has been driven by emerging markets such as China and Eastern Europe, the developed markets of North America, Western Europe and the Pacific Rim together account for over 50% of global OTC turnover.
  • Although most Rx-to-OTC switches are driven by manufacturers; governments around the world increasingly view Rx-to-OTC switching as a means of relieving pressure on overburdened health insurance systems.
  • Throughout the world, access to OTCs is increasing. In some countries, the increased access is derived mainly from pioneering switches from Rx-to-OTC; while, in others, the increased access is derived mainly from the opening up of distribution channels and from an easing of advertising restrictions.
Key findings from this report
  • In all seven featured countries, OTC market expansion is being fuelled by Rx-to-OTC switching.
  • The success of new-generation switches often relies on a collaborative care model, involving co-operation between consumers, doctors and pharmacists.
  • In the future, the collaborative care model could potentially be used as a basis for switching products for treating conditions such as asthma, hypertension, hyperglycemia and osteoporosis. There is also scope for switching products for treating conditions for which the timing of treatment is critical: for example, adrenaline injectors containing epinephrine and antivirals such as Roche’s Tamiflu (oseltamivir).

Key questions answered
  • What opinion do various stakeholders (i.e. consumers, regulators, manufacturers, healthcare professionals) have on Rx-to-OTC switches?
  • What does the future hold for the global OTC market?
  • What Rx-to-OTC switches might there be in the future?
About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , , , , , |

ReportsandReports - The Top 10 US Specialty Chemicals Companies: Response to recession, growth strategies and SWOT analysis

The specialty chemicals operations of major US players remained relatively resilient during the downturn compared to their other business lines. The 2005-09 period also witnessed a considerable rise in consolidation activities among US companies. Some players are focused on backward integration of operations whilst others are aiming to offload non-core franchises. Consolidation is in part prompted by fluctuations in raw material prices and rising competitiveness in the global marketplace.
The report profiles major US players in the specialty chemical segment and elucidates trends associated with these companies, and insights into the opportunities and threats facing them.. This report provides detailed profiles of ten leading US specialty chemicals companies, containing descriptions of business, financial performance, growth strategies and SWOT analysis.
Key features of this report
  • Key drivers and resistors to growth of leading US specialty chemicals companies.
  • Common industry characteristics in strategies and performance of US specialty chemicals companies.
  • Analysis of financial performance and growth strategies of leading specialty chemicals companies during 2005–09.
  • Overview of specialty chemicals product portfolios of leading companies.
  • SWOT analysis of the leading US specialty chemicals companies.
Scope of this report
  • Learn from the strategies of US specialty chemicals companies to target future growth markets effectively, avoid their mistakes, replicate their successes and learn of the threats they face.
  • Benchmark your performance against the leading US specialty chemicals companies by understanding their strategies.
  • Measure the resistance of specialty chemicals operations of US companies during the economic downturn.
  • Compare performances of specialty and non-specialty chemicals operations of US companies during the recent global recession.
  • Save time, money and resources on analyzing the performance of leading specialty chemicals companies using this report.
Key Market Issues
  • Raw material price fluctuations: Review of the 2005-09 period indicates that profits of specialty chemicals operations of leading US players are influenced by fluctuations in raw material prices. Fall in prices during the economic downturn had considerable effects on operating margins of US players.
  • Fall in demand during downturn: Fall in demand considerably suppressed operating income of US companies in 2009. However, prompt restructuring activities enabled several companies to maintain steady levels of operating margin.
  • Relative resistance of specialty chemicals operations: Business Insights observes that the impact was less profound when compared to non-specialty chemicals. The contribution of specialty chemicals to the decline in consolidated revenues was relatively modest. Our in house developed Revenue Growth Index clearly differentiates the performance of specialty and non-specialty operations of US players.
  • Consolidation: US players are focused on consolidating their position in the global specialty chemicals market through backward integration and shifting attention to core franchises. Rohm and Hass was acquired by Dow Chemicals while Hercules was taken over by Ashland.
Key findings from this report
  • The 10 leading US companies generated $13.3bn sales in 2009, accounting for 4.6% of the $288bn global specialty chemicals market.
  • Huntsman was the largest US specialty chemicals company with $3.8bn sales in 2009.
  • US specialty chemicals companies were not insulated from the fall in volume sales experienced by the global chemicals industry due to the economic downturn. The majority of these players were affected by the fall in industrial input costs as was observed in their selling prices.
  • Business Insights’ Revenue growth index indicates that during the downturn, specialty chemicals businesses of US players performed better than their non-specialty operations.
Key questions answered
  • What was the market size of the global specialty chemicals industry by value in 2009?
  • What will be the market size of the global specialty chemicals industry during 2010-14?
  • What are the key trends observed in the US specialty chemicals companies and strategic responses that are taking shape?
  • Who are the major US players in the global specialty chemicals market?
  • What are the growth strategies of the leading 10 companies?
  • What are the strengths, weaknesses, opportunities and threats facing the top 10 players?
About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , |

ReportsandReports - The Impact of US Healthcare Reform on Pharma: Analyzing the effects



This report carries out a detailed analysis of the provisions of healthcare reform and their effects on the pharmaceutical industry. Strategies for optimizing promotional activities and pipelines for the future are examined.

After a year of debate and negotiation, in 2010, President Obama signed wide-ranging health reform into law. R&D priorities, pharmaceutical promotion, and pricing and reimbursement will all be impacted. The financial impact on pharma will be negative to 2014, then positive between 2014 and 2019 once large numbers of the uninsured gain cover. The net impact is neutral.

This report provides the most detailed review of the effects on the pharma industry available at the time of going to press. Contains a model of the financial impact on the industry. Uses IMS data to model Medicaid and Medicare impact on individual companies.

Key features from reading this report
  • Provides a detailed review of the provisions of US healthcare reform including the time they become effective.
  • Analyses the companies most exposed to Medicare and Medicaid rebates and discounts.
  • Proposes strategies from minimizing the negative impacts of reform.
  • Includes a detailed analysis of the history and background to health reform.
  • Examines trends in pharmaceutical promotion,pricing and reimbursement.
Key benefits of this report
  • Understand in detail and anticipate the measures included in healthcare reform.
  • Learn how to adapt promotional strategies to the evolving regulatory and reimbursement environment.
  • Assess R&D priorities against the changing market.
  • Gain insight into the dynamics of the US healthcare system and pharmaceutical market.
  • Develop strategies for efficient compliance with the provisions of healthcare reform.
Key questions answered by this report
  • What effects will the changes to Medicare Part D have on the generics and branded drug markets?
  • What effects will the new approval pathway for biosimilars have on the biologics market?
  • How will the changes to the health insurance market affect drug prices and revenues?
  • What will the long-term effects of healthcare reform different parts of the pharma industry?
  • Which strategies will enable pharma companies to adapt to optimize their revenues in the evolving market environment?
  • Which companies will be most impacted by Medicaid rebates and Medicare discounts?
  • How will new transparency rules affect the way pharmaceutical companies promote their products?
  • How will comparative effectiveness affect the pharmaceutical industry?
About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , , |